C7 Antibody - #DF9410
| 製品: | C7 Antibody |
| カタログ: | DF9410 |
| タンパク質の説明: | Rabbit polyclonal antibody to C7 |
| アプリケーション: | WB IHC |
| 反応性: | Human, Mouse |
| 予測: | Pig, Bovine, Horse, Sheep, Rabbit, Dog |
| 分子量: | 94kDa; 94kD(Calculated). |
| ユニプロット: | P10643 |
| RRID: | AB_2842606 |
製品説明
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
引用形式: Affinity Biosciences Cat# DF9410, RRID:AB_2842606.
折りたたみ／展開
C7; CO7_HUMAN; complement component 7; Complement component C7;
免疫原
- P10643 CO7_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MKVISLFILVGFIGEFQSFSSASSPVNCQWDFYAPWSECNGCTKTQTRRRSVAVYGQYGGQPCVGNAFETQSCEPTRGCPTEEGCGERFRCFSGQCISKSLVCNGDSDCDEDSADEDRCEDSERRPSCDIDKPPPNIELTGNGYNELTGQFRNRVINTKSFGGQCRKVFSGDGKDFYRLSGNVLSYTFQVKINNDFNYEFYNSTWSYVKHTSTEHTSSSRKRSFFRSSSSSSRSYTSHTNEIHKGKSYQLLVVENTVEVAQFINNNPEFLQLAEPFWKELSHLPSLYDYSAYRRLIDQYGTHYLQSGSLGGEYRVLFYVDSEKLKQNDFNSVEEKKCKSSGWHFVVKFSSHGCKELENALKAASGTQNNVLRGEPFIRGGGAGFISGLSYLELDNPAGNKRRYSAWAESVTNLPQVIKQKLTPLYELVKEVPCASVKKLYLKWALEEYLDEFDPCHCRPCQNGGLATVEGTHCLCHCKPYTFGAACEQGVLVGNQAGGVDGGWSCWSSWSPCVQGKKTRSRECNNPPPSGGGRSCVGETTESTQCEDEELEHLRLLEPHCFPLSLVPTEFCPSPPALKDGFVQDEGTMFPVGKNVVYTCNEGYSLIGNPVARCGEDLRWLVGEMHCQKIACVLPVLMDGIQSHPQKPFYTVGEKVTVSCSGGMSLEGPSAFLCGSSLKWSPEMKNARCVQKENPLTQAVPKCQRWEKLQNSRCVCKMPYECGPSLDVCAQDERSKRILPLTVCKMHVLHCQGRNYTLTGRDSCTLPASAEKACGACPLWGKCDAESSKCVCREASECEEEGFSICVEVNGKEQTMSECEAGALRCRGQSISVTSIRPCAAETQ
種類予測
Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.
High(score>80) Medium(80>score>50) Low(score<50) No confidence
PTMs - P10643 基板として
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| W36 | C-Glycosylation | Uniprot | |
| N202 | N-Glycosylation | Uniprot | |
| S228 | Phosphorylation | Uniprot | |
| S229 | Phosphorylation | Uniprot | |
| S331 | Phosphorylation | Uniprot | |
| W503 | C-Glycosylation | Uniprot | |
| W506 | C-Glycosylation | Uniprot | |
| W509 | C-Glycosylation | Uniprot | |
| T696 | O-Glycosylation | Uniprot | |
| N754 | N-Glycosylation | Uniprot | |
| S834 | Phosphorylation | Uniprot |
研究背景
Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C7 serves as a membrane anchor.
C7 has 28 disulfide bridges.
C-, N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
Secreted.
Monomer or dimer; as a C5b-7 complex it can also form multimeric rosettes. MAC assembly is initiated by proteolytic cleavage of C5 into C5a and C5b. C5b binds sequentially C6, C7, C8 and multiple copies of the pore-forming subunit C9.
Belongs to the complement C6/C7/C8/C9 family.
研究領域
· Human Diseases > Neurodegenerative diseases > Prion diseases.
· Human Diseases > Immune diseases > Systemic lupus erythematosus.
· Organismal Systems > Immune system > Complement and coagulation cascades. (View pathway)
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.